Search
REP8839
go.drugbank.com/drugs/DB05224ExperimentalREP8839 is a novel methionyl-tRNA synthetase (MetS) inhibitor being developed by Replidyne (GlaxoSmithKline licensed REP8839 to Replidyne in June of 2003).
Interferon gamma-1b
go.drugbank.com/drugs/DB00033ApprovedInvestigationalPurification of the product is achieved by conventional column chromatography. … The sequence displayed is a cDNA sequence which codes for human interferon gamma, as described by Gray et. al. and not specifically interferon gamma 1b.
Fluciclovine (18F)
go.drugbank.com/drugs/DB13146ApprovedInvestigational[A31384] The structure of fluciclovine allows it to be uptaken by the tumoral cells by its amino acid transporter without incorporating in the metabolism within the body. … [A31385] Fluciclovine was developed by Blue Earth Diagnostics, Ltd. and FDA approved in May 27, 2016.[L1049]
Boldenone
go.drugbank.com/drugs/DB01541ExperimentalIllicitVet approvedIt is not indicated for use in humans in the US and is only available through veterinary clinics.
Mebanazine
go.drugbank.com/drugs/DB09248ApprovedWithdrawnIt was used in the past as an antidepressant in the 1960s, but has since been discontinued because of its hepatotoxic potential.
Tetrabenazine
go.drugbank.com/drugs/DB04844ApprovedA drug formerly used as an antipsychotic but now used primarily in the symptomatic treatment of various hyperkinetic disorders.
Lactulose
go.drugbank.com/drugs/DB00581ApprovedInvestigationalLactulose is a synthetic disaccharide derivative of lactose that is most commonly used as a laxative agent despite also being formally indicated to serve as an adjunct therapy in treating portal-systemic encephalopathy (PSE).[FDA Label,L...
Chlorzoxazone
go.drugbank.com/drugs/DB00356ApprovedIt is claimed to inhibit muscle spasm by exerting an effect primarily at the level of the spinal cord and subcortical areas of the brain. (From Martindale, The Extra Pharmacopoea, 30th ed, p1202)
Plecanatide
go.drugbank.com/drugs/DB13170ApprovedInvestigationalPlecanatide is a drug approved in January 2017 by the FDA for the treatment of chronic idiopathic constipation (CIC).
Monobenzone
go.drugbank.com/drugs/DB00600ApprovedWithdrawnIt exerts a depigmenting effect on skin of mammals by increasing the excretion of melanin from the melanocytes. It may also cause destruction of melanocytes and permanent depigmentation.